Drugs / quadrivalent influenza split vaccine
quadrivalent influenza split vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05212623 | Oct 2021 → Jan 2022 | influenza | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-10-27 | Sinovac Biotech Co., Ltd | Results 研究显示：3-8岁儿童接种2针流感疫苗能获得更佳保护 sinovac.com ↗ |
| 2020-12-14 | CSL Behring | Results Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020 csl.com ↗
A Late-breaking poster presentation demonstrating that QIVc prevented significantly more influenza-related medical encounters among individuals aged ≥4 years (n=2,113,216) with at least one health condition, compared to QIVe in the 2018/19 U.S. influenza season. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-10-27 | Sinovac Biotech Co., Ltd | 研究显示：3-8岁儿童接种2针流感疫苗能获得更佳保护 sinovac.com ↗ |
| 2020-12-14 | CSL Behring | Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020 csl.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | quadrivalent influenza split vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05212623 ↗ |
| Known as | IIV4 | “a quadrivalent inactivated influenza vaccine (IIV4) at 0.25 mL” NCT05212623 ↗ |
| Known as | quadrivalent inactivated influenza vaccine | “a quadrivalent inactivated influenza vaccine (IIV4) at 0.25 mL” NCT05212623 ↗ |
| Modality | Vaccine | “quadrivalent influenza vaccine” NCT05212623 ↗ |
| Route | Intramuscular | “by intramuscular injection” NCT05212623 ↗ |